Dr. Oscar Cingolani

Dr. Cingolani is an Associate Professor at The Johns Hopkins University School of Medicine, Division of Cardiology. He earned his medical degree from Universidad Nacional de La Plata, Argentina, and completed his Internship and Internal Medicine Residency at CEMIC, Buenos Aires, Argentina, and hypertension research post-doctoral fellowship at Henry Ford Hospital, Detroit, MI. After completing his Internal Medicine Residency at The Reading Hospital and Medical Center in Pennsylvania, Dr. Cingolani joined The Johns Hopkins Hospital as a Cardiology fellow, where he remained in the Faculty after his training. Currently, he is the Associate Director of The Johns Hopkins Hospital Coronary Care Unit, Director of the Hypertension Center and member of the Echocardiography Lab and Outpatient Cardiology Clinic. He also teaches pathophysiology to medical students. Dr. Cingolani’s research interests focus on hypertensive heart disease and its transition to heart failure. He aims to elucidate the mechanism/s by which certain matricellular proteins present in the heart seem to play a protective role. His research is mainly supported by the National Institute of Health (NIH). He is also the principal investigator of the DREAM study group, studying the effect of Melatonin in preventing atrial fibrillation in patients undergoing cardiac surgery. Dr. Cingolani has been recognized by the Council for High Blood Pressure Research of the American Heart Association for his work in hypertension and is the 2011 recipient of the PJ Schafer Memorial Heart Research Award, the 2012 Michel Mirowski Discovery Fund Award, and 2013 Magic that matters Fund.

Dr. Cingolani is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Paroxysmal Supraventricular Tachycardia (PSVT), Multifocal Atrial Tachycardia, His Bundle Tachycardia, Cardiac Ablation, and Tissue Biopsy.

Dr. Cingolani is board certified in American Board Of Internal Medicine. He is actively involved in clinical research, co-authoring 27 peer reviewed articles and participating in 1 clinical trial.